Herpes simplex viruses type 1 (HSV-1) that lack the g 1 34.5 gene are unable to replicate in the central nervous system (CNS), but maintain replication competence in actively dividing tumors. To determine if antitumor therapy by M002, a g 1 34.5
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Because of poor survival of patients with primary intracranial malignancies, novel therapeutic approaches, most notably viral and gene therapy, have been investigated (for reviews, see Markert et al 2, 3 and Andreansky et al 4) . We and others have reported on the efficacy of using neuroattenuated replication-competent herpes simplex viruses (HSV) for the treatment of primary brain tumors. These viruses typically contain one or more mutations within the viral genome, including thymidine kinase (tk), 5 ribonucleotide reductase (U L 39), 6, 7 UTPase 8 or g 1 34.5. 9, 10 The g 1 34.5 gene of HSV is present in two copies and located within the inverted repeats of the unique long segment. Mutations within this gene have been shown previously to cause reduction in viral replication and associated neurovirulence of HSV. 11 Thus, g 1 34.5-deleted HSV are able to selectively replicate and destroy glioma cells in vivo, without damaging surrounding brain tissue. Moderate increases in longterm survival for engineered HSV-treated versus untreated animals have been reported in both syngeneic and xenogeneic murine tumor models of GBM. 5, 9, 10, [12] [13] [14] [15] [16] In addition, Phase I studies in humans with malignant glioma have demonstrated that two g 1 34.5-deleted HSV, G207 and 1716, are safe for intracranial inoculation, [17] [18] [19] albeit at different quantities of inoculated virus. G207, which contains mutations within both copies of the g 1 34.5 gene and in the U L 39 gene, has been safely administered at doses up to 3 Â 10 9 plaque forming units (PFU). Despite these advantages, existing experimental data suggest that multiple modalities of therapy will be necessary to eradicate malignant tumors of the central nervous system (CNS) as well as those originating outside the brain. To increase the efficacy of antineoplastic therapy, we have been studying oncolytic HSV as vectors for gene therapy. These HSV, which contain identical deletions within both copies of the g 1 34.5 gene, retain the ability to replicate in and lyse rapidly dividing cells, such as found in tumors, but are unable to replicate in postmitotic cells, such as those found in normal adult CNS. These conditionally replication-competent HSV have been engineered to express foreign genes designed to augment their antitumor effects. Initially, HSV mutants that express interleukin-4 (IL-4) or IL-10 were evaluated in an orthotopic model of murine GBM utilizing syngeneic GL-261 tumors implanted into immunocompetent C57BL/6 mice. 14 In this model, treatment with IL-4-expressing HSV increased survival over treatment with HSV alone, suggesting that cytokine gene therapy may mediate enhanced tumor-specific killing. IL-4 gene therapy has been shown to enhance antiglioma effects in several gene therapy models. [20] [21] [22] Such effects are T H 2-mediated and have been attributed to CD4 þ lymphocytes and other effector cells such as eosinophils. 23 While IL-4 was effective in these animal models, we hypothesized that a more durable antitumor effect would be achieved through generation of a T H -1 response, including the induction of a memory response against tumor cells. Toward this end, we recently constructed and characterized a conditionally replication-competent HSV-1 expressing IL-12 (M002). IL-12 is a cytokine that mediates the T H 1-type immune response, stimulates natural killer (NK) cell activity, and has also been shown to have antiangiogenic properties [24] [25] [26] It has known antitumor properties in a variety of models. 25, 27 We have previously demonstrated that a g 1 34.5-deleted HSV-1 expressing murine IL-12 (M002) prolonged survival of immunocompetent mice in an experimental intracranial murine model of neuroblastoma. 28 Recently, combinatorial cytokine therapy has been pursued in a wide array of cancer therapies. IL-12 has been shown to have increased antitumor effects when used in combination with additional cytokines. 27 Because of its ability to stimulate chemotaxis of monocytes and numerous T-lymphocyte subsets, monocyte chemoattractant protein-1 (MCP-1), now called CCL2, is potentially a good candidate for increasing the antitumor effects of IL-12. CCL2 is a member of the C-C chemokine family and stimulates chemotaxis of monocytes, CD4 þ and CD8 þ , memory T lymphocytes and dendritic cells in vitro. 29, 30 An augmented antineoplastic effect could potentially be produced by an increased availability of CD4 þ , CD8
þ , NK and dendritic cells available for activation by IL-12, as well as a differential effect on macrophages of CCL2 stimulation in the presence of IL-12. 31, 32 We hypothesized that an HSV expressing CCL2 in combination with M002 would enhance tumor killing when compared with tumors treated with either virus alone. To test this hypothesis, we have constructed a conditionally replication-competent (g 1 34.5-deleted) HSV-1 vector that expresses CCL2 (M010), similar to M002. To summarize our results, we have demonstrated the following: (1) M010 expresses physiologically relevant levels of CCL2; (2) M010 is not neurotoxic and can be safely inoculated into murine brain at doses up to 5 Â 10 7 PFU, the maximum dose tested to date; (3) coadministration of M010 with M002 in a syngeneic flank tumor model of a nervous system tumor produced increased antitumor effects over either virus when administered alone; (4) this increased antitumor effect was statistically significant; and (5) immunohistochemical analysis of HSV-treated flank tumor sections demonstrated a greater influx of CD4 þ and CD8 þ T cells into tumors treated with a combination of M002 and M010 when compared with tumors treated with either virus alone. These data provide additional support for the use of combination immunotherapy for treatment of nervous system malignancies to enhance the antitumor effects of HSV-derived vectors.
Materials and methods

Cells
Vero cells (American Type Culture Collection (ATCC), Rockville, MD) were grown and maintained in minimal essential medium (Cellgro, Mediatech Inc., Herndon, VA) containing 7% fetal bovine serum (FBS). The human 143 thymidine kinase minus cells (143tkÀ, ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM) (Cellgro) supplemented with 10% FBS. Rabbit skin cells (originally acquired from Dr J McClaren, University of New Mexico, Albuquerque, NM, USA) were maintained in DMEM supplemented with 5% FBS. The murine neuroblastoma cell line Neuro-2a (derived from strain A/J mice) was purchased from the ATCC (CCL 131, passage 171) and was maintained in a 50:50 mixture of DMEM and Ham's Nutrient Mixture F-12 (DMEM/F12) supplemented with 2.6 mM L-glutamine and 7% FBS.
Plasmids and viruses
HSV-1 (F) strain is a low-passage clinical isolate used as the prototype HSV-1 strain in our series. 33, 34 Virus R3659 has been described previously. 35 Construction of M002, which expresses murine IL-12 (mIL-12) under the transcriptional control of the murine early growth response-1 promoter (Egr-1), has been described previously. 28 The murine clone for CCL2 (monocyte chemotactic protein or MCP-1, homologous to mouse Sig-je) was obtained from ATCC (Rockville, MD). The HSV shuttle plasmid pRB4878 has been previously described.
14 Plasmid 4878-MCP1 was constructed as follows: a 604 bp fragment containing the entire coding sequence of murine CCL2 was removed from pGEM-1 by EcoR1 restriction digestion, ends blunted using the large (Klenow) fragment of DNA polymerase I, and subcloned into a blunted KpnI site located between the Egr-1 promoter and hepatitis polyA sequences within pRB4878. All restriction and modifying enzymes were purchased from Invitrogen Life Technologies (Carlsbad, CA). To generate M010, the targeting plasmid 4878-CCL2 was cotransfected with HSV-1 DNA R3659 36 using 15 ml Lipofectamine (Invitrogen). Recombinant tk-negative viruses were selected using the standard tk selection method, 33 and the tk gene was repaired at its native locus, as previously described for M002. 28 Introduction of CCL2 under the control of the Egr-1 promoter into the g 1 34.5 locus, and repair of tk at its native locus, was confirmed by Southern blot hybridization (data not shown).
ELISA
Production of murine CCL2 by M010 was confirmed and quantified using a commercially available ELISA kit (R&D Systems, Minneapolis, MN), whereas IL-12 production by M002 has been demonstrated previously. 28 For in vitro CCL2 production, six-well plates were seeded at a confluency of 1.5 Â 10 5 (Vero) or 4 Â 10 5 (Neuro-2a) cells/well 1 day prior to infection with desired recombinant or control virus at a multiplicity of infection (MOI) of 1 in a total volume of 0.5 ml. After 2 hours, inoculum was removed, 1 ml of growth medium was overlaid onto infected wells and plates were incubated for 24 hours at 371C. The supernatants were removed, and appropriately diluted samples were analyzed by ELISA, according to the manufacturer's protocol. Experiments were performed in duplicate and the average level of cytokine production was determined, and levels detected were well within the range of the kit sensitivity (15.6-1000 pg/ml). For analysis of IL-12, interferon gamma (IFN-g) or CCL2 production in Neuro-2a flank tumors, tumors were established as described below, until the appropriate size was achieved. Tumors were injected with 1 Â 10 7 PFU of either M002 or M010 in 50 ml total, or with 50 ml of serum-free DMEM. Animals were killed and tumors removed at days 3, 6, 10 or 13 after treatment, weighed and diluted 1:5 (w/v) with DMEM:F12 containing 1% FBS. Tumors were homogenized and 0.1 ml of the homogenate supernatants (i.e. 20 mg of tumor) was analyzed for IL-12, IFN-g or CCL2 production by ELISA using commercially available kits (R&D Systems) as described above. At least two mice were analyzed per time point. Cytokine production was standardized to the weight of the tumor (pg/ml cytokine per 20 mg tumor).
Animals
Specific pathogen-free female A/J strain mice were obtained from Charles River Laboratories and used at approximately 8 weeks of age. All animal studies were conducted in accordance with guidelines for animal use and care established by The University of Alabama at Birmingham Animal Resource Program and the Institutional Animal Care and Use Committee (IACUC protocol numbers 000203985, 000903963 and 020506278).
Neuro-2a flank tumor model
To establish Neuro-2a flank tumors in A/J mice, cultured Neuro-2a cells were trypsinized and seeded at 3.0 Â 10 6 cells, or higher, in 0.2 ml serum-free DMEM and injected subcutaneously implanted into the right flanks of 6-to 8-week-old A/J mice. When palpable tumors were detected, typically 5-7 days after tumor cell implantation, animals were weighed and tumors were measured using vernier calipers. Due to significant heterogeneity in initial tumor volume of the animals, care was taken to distribute evenly the animals with the largest and the smallest tumors across all the treatment groups such that the average starting tumor volume for all the mice within each treatment group was approximately the same. After direct intratumoral virus injection, tumors were measured twice weekly, and animals were monitored closely for substantial weight loss (420% initial body weight), adverse changes in grooming habits, signs of dehydration or development of ulcerating or cannibalized tumors. Tumor growth inhibition was monitored for 3 weeks. If during this period any significant morbidity was observed (see criteria above), or if any given tumor measurement parameter (l,w,h) exceeded 25 mm, animals were euthanized.
Statistical analyses
Changes in tumor volume after virus (or vehicle) treatment were analyzed as follows. To adjust for heterogeneity between animals in initial tumor size, changes in tumor volume were expressed as a proportion of the volume on day zero. Since the distribution of the outcome variable was highly skewed, a log transformation was used to both reduce the variability and make the distribution as close to a normal distribution as possible. A linear mixed model with an autoregressive covariance structure was first fit to the data from each experiment separately, and then to the combined data from both experiments. The predictors in the model were weight of the mouse, the volume, time, treatment and the interaction between time and treatment.
Histopathology
Neuro-2a flank tumors were harvested from killed animals and divided into three approximately equal sections by free hand slicing. The sections were placed in a freezing cassette that was filled with Tissue-Tek OCT compound, and placed on a block of dry ice until frozen, then stored at À801C. Frozen tumors were sectioned (8 mm thick), mounted on TEPSA-coated slides, fixed in 95% ethanol and blocked first in 5% normal rabbit serum (Vector Laboratories, Burlingame, CA), diluted in 1 Â PBS for 30 minutes at room temperature (RT), followed by avidin (15 minutes, RT) and biotin (15 minutes, RT). One slide of each group was stained with hematoxylin and eosin (SurgiPath Medical Industries Inc., Richmond, IL). Serial sections were reacted with rat monoclonal antibodies specific for mouse CD4 (clone GK1.5) and CD8 (clone 53-6.7) surface antigens (BD Biosciences Pharmingen, San Jose, CA) and the antibody binding detected using biotinylated rabbit anti-rat Ig (Vector Laboratories) followed successively with an avidinbiotin-horseradish peroxidase complex and 1% diaminobenzidine 14 (Vectastain ABC kit, Vector Laboratories). The staining was carried out according to the kit protocol.
Results
A recombinant g 1 34.5-deleted HSV that expresses CCL2 for tumor therapy
We have previously demonstrated that recombinant HSV that express murine IL-4 (R8306) or murine IL-12 (M002) could significantly improve survival when injected into tumors implanted in brains of immunocompetent mice in a syngeneic murine model. 14, 28 We hypothesized that intratumoral CCL2 expression would enhance recruitment of monocytes into the tumors and would increase the antitumor activity of M002. To test this hypothesis, we constructed a recombinant, g 1 34.5-deleted HSV that expresses CCL2 (M010), as described in Materials and methods. The genomic organization of M010 is illustrated in Figure 1 . To determine whether each of the viruses was expressing physiologically relevant levels of the respective cytokine or chemokine, we quantified culture supernatants from Vero and Neuro-2a cells infected with M010 for CCL2 production by ELISA, as described in Materials and methods. In Vero cells, physiologically relevant levels of CCL2 were produced, 37 ranging between 2 and 5 nM, as shown in Table 1 . In Neuro-2a cells, 0.2 nM of CCL2 was produced after 48 hours infection, which is also within physiologically relevant levels (B0.1-9 nM).
Combinatorial cytokine therapy of Neuro-2a flank tumors using M002 and M010
The Neuro-2a spontaneous neuroblastoma of A/J mouse origin has been previously shown to be susceptible to HSV-1 infection. 38 When injected subcutaneously, Neuro2a cells are able to establish sizable tumors on the mouse flank in a relatively short time. Neuro-2a is one of several clonal derivatives of the C-1300 spontaneous neuroblastoma of A/J mice, and has been used previously for evaluating multiple therapeutic modalities. 39 The tumor exhibits low immunogenicity, including low levels of MHC I, MHC II and B7.1 expression, and is thus a stringent test for preclinical models of antitumor immunotherapy. 28 The Figure 2 . For the combination treatment group, equivalent amounts of each virus were injected such that the total PFU administered was equal to that given in the single virus treatment groups. For example, in the combination treatment group, 5 Â 10 6 PFU M002 þ 5 Â 10 6 PFU M010 was administered for the first two doses, which was equivalent to the first two doses of 1 Â 10 7 PFU each administered in the single virus groups. The flank tumor growth inhibition studies were performed in two separate experiments, and the average tumor volume for all of the mice in each treatment group (n ¼ 10) at each time point was determined. In the first experiment, groups treated with M002, M010 or a combination of the two inhibited tumor growth more effectively than groups treated with DMEM (virus diluent) only, or with the parent virus R3659 (Fig 3) . For the M002 þ M010 combination group, the average tumor volumes obtained in the third week of monitoring were less than the average tumor volumes obtained for either the M002 or M010 treatment groups, suggesting that combinatorial therapy was more effective than therapy with either virus alone. In the second experiment, the data varied slightly in that the average tumor volume from the M010-only treatment group did not show any growth inhibition when compared with the R3659 treatment group (data not shown). Further, growth inhibition of tumors treated with the M002 þ M010 combination group was more pronounced in the second experiment, with the effect appearing after the first week of the 3-week monitoring period (data not shown).
Statistical analysis of inhibition of flank tumor growth by cytokine-expressing HSV-1
To determine whether the trends observed for inhibition of tumor growth over time were of significance in the two separate experiments, the data from each experiment were submitted for statistical analysis. Since the variable of interest in each experiment was the rate of change of the mean tumor volume across time in the different treatment groups, the linear model was used to compare the slopes of the different treatment groups. This allows for the modeling of the covariance structure within the repeated measurements for each mouse. The log transformations of the mean tumor volumes for each group were then compared using Wald's test, which assumes normality.
The results showed that time, weight and the interaction term were all highly significant, and suggested that the effect of treatment on the tumor volume was a function of the number of days post inoculation. This was true whether the data from the experiments were analyzed separately or combined for the two studies. Table 2 displays the difference in log mean tumor volumes between the vehicle (DMEM) and the four other treatments at the different time points in the two experiments. In both experiments, the combination of M010 and M002 reduced tumor volume faster than treatment with either of the two viruses individually. In the first experiment, the magnitude of differences in the log tumor volumes when compared to controls was consistently higher in the combination treatment group than in the treatment groups, which received only M010 or M002 ( Table 2 ). The second experiment varies from the first in that statistically significant reduction in tumor HSV-1 expressing CCL2 and IL-12 for antitumor therapy JN Parker et al volume was not observed in the M010-only treatment group. However, as in the first experiment, the differences in tumor volumes for treatment groups, which received a combination of M002 with M010, were significantly different from the control treatment group tumors. The time to achieve significant differences occurred much earlier for the combination treatment group (day 7) versus the M002-only treatment group (day 14).
Evaluation of in vivo cytokine/chemokine expression in Neuro-2a flank tumors treated with recombinant HSV at various time points post tumor therapy
To assess in vivo the levels of IL-12 and CCL2 production over time within each treatment group, tumor-bearing mice were injected intratumorally with 1 Â 10 7 PFU of either R3659, M002, M010, or M002 in combination with M010. At days 3, 6, 10 and 13 post virus injection, two mice/group were killed, tumors harvested, homogenized and homogenates analyzed by ELISA for IL-12 or CCL2 production, as described earlier. In addition, since IL-12 enhancement of a T H 1-type immune response is mediated via the induction of IFN-g secretion, IFN-g production was also assessed by ELISA. Figure 4 graphically illustrates the relative levels of each of these proteins over time for each treatment group. IL-12 and early IFN-g protein levels were highest in tumors treated with M002 only, with no IL-12 production in tumors treated with the parent virus R3659, or with M010 (CCL2-expressing HSV). For tumors treated with both M002 and M010, IL-12 levels were approximately the same at day 3, but significantly more IL-12 was produced at day 6 in the M002-only treatment group, indicating no further contribution of CCL2 to its production. For the latter time points, the error margins were significantly greater for the M002-only treatment group. Thus, it is difficult to ascertain whether the elevated IL-12 levels at these time points, as compared to the combination of M002 and M010 treatment group, are a real effect. Interestingly, the combination of M002 and M010 had significantly elevated levels of IFN-g at the last time point evaluated (day 13) versus IFN-g levels detected in homogenates of tumors treated with M002 only. Between 1 and 2 ng/ml of CCL2 is produced in Neuro-2a tumors after HSV (R3659) infection. In tumors treated with M002 or M010 only, the levels of CCL2 are similar at days 3 and 6, and remain essentially the same even after combinatorial therapy. As with the IFN-g production, day 13 levels of CCL2 are high in the combination group.
Evaluation of immune cell infiltrates in Neuro-2a tumors treated with recombinant HSV at various time points post tumor therapy
For immunohistochemical analysis of immune cell infiltrates into the tumors following HSV therapy over time, Neuro-2a flank tumors were established as before, and 1 Â 10 7 total PFU administered for each treatment group on day 0. At days 3, 6, 10 and 13, two mice/group were euthanized, their tumors excised and frozen tissue sections were prepared and labeled with rat monoclonal antibodies specific for CD4 þ and CD8 þ T cells (see above). Immunohistochemical staining was performed as described in Materials and methods. Representative staining patterns of tumor sections for the different treatment groups are shown in Figure 5 for days 6 and 13. To quantify and compare the numbers of CD4 þ and CD8 þ cells elicited after treatment for a given time point, representative tissue sections were photographed at Â 200 magnification and number of positive cells/field was determined by visual counting (Table 3) . Tumors treated with a combination of M002 and M010 elicited significant CD8 þ T-cell responses, which were highest at days 3 and 6 after treatment (100-200 positive cells/field), but remained significant at days 10 and 13 post treatment (50-100 positive cells/field). Modest CD4 þ T-cell responses were detected at days 3 and 6 post virus treatment (o100 positive cells/field), but were significantly enhanced by days 10 and 13 (4100 positive cells/field), which was considerably more than any other treatment group at the latter time points. M002-only-treated tumors also elicited significant CD4 þ (150-160 positive cells/ field) and CD8 þ T-cell responses (4200 positive cells/ field), but they did not appear until day 6 (o10 CD4 þ or CD8 þ cells/field detected at day 3), were reduced at day 10 (o100 positive cells/field) and then reappeared in significant levels by day 13 (4200 CD8 þ T cells/field were detected at the latest time point assessed). The M010-only treatment group elicited modest CD4 þ T-cell responses (o100 positive cells/field), which remained essentially unchanged for all of the time points assessed. IL-12 is a heterodimeric cytokine with potent antitumor properties. It is produced by macrophages, monocytes, B cells dendritic cells and other antigen-presenting cells. 27 It acts to enhance the cytolytic activity of NK cells and cytotoxic T lymphocytes as well as the development of a T H 1-type immune response via the induction of IFN-g secretion. Indeed in flank tumors treated with M002 alone, IFN-g levels were significantly greater at days 3 and 6, as compared to levels detected from tumor homogenates from the other treatment groups, as determined by ELISA.
IL-12 also possesses antiangiogenic properties, which likely represents an additional mechanism for its antitumor activity.
26,27 IL-12 has been shown to produce antiglioma immune activity in a murine model. 40 Its proinflammatory effects that do not rely on an intact IL-2 receptor pathway have been suggested as a potentially important approach for immunotherapy.
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CCL2 is a C-C chemokine that directs the leukocytes to infiltrate tissues in order to produce an inflammatory response. CCL2 stimulates the influx of CD4 þ , CD8 þ , NK and dendritic cells, as well as macrophages. CCL2 has also been shown to bind to the abluminal side of brain microvessels and stimulate trafficking of mononuclear cells into the CNS parenchyma to await further activation. 42 While CCL2 levels are often elevated within gliomas, the absolute level of cytokine and chemokine expression can produce differing effects on target cells. Additionally, the production of a T H 1 versus T H 2 response by CCL2 and its receptor CCR2 is known to depend on the local tissue environment, the timing of CCL2 induction, the type of antigen, route of inoculation/ immunization and the tissue site. 31 It has been reported previously that codelivery of a recombinant adenovirus (rAd) expressing CCL2 into tumor cells with a rAd that expressed HSV tk demonstrated enhanced antitumor effects in hepatocellular carcinoma, 43 as did a more recently described bicistronic rAd that expressed both CCL2 and HSV tk. 44 In this study, we investigated the efficacy of coadministration of two conditionally replication-competent HSV that express either CCL2 or IL-12 for antitumor therapy in a flank tumor model. For simplicity, we initially chose coadministration of these two viruses, at an equivalent ratio. It is, however, quite possible that coadministration of CCL2 and IL-12 does not provide the optimal antitumor effect, which might be better achieved by altering the ratios of the two viruses, by sequential administration or a combination thereof. While statistically significant inhibition of flank tumor growth was HSV-1 expressing CCL2 and IL-12 for antitumor therapy JN Parker et al observed with coadministration of the viruses at equal proportions in the present study, we are currently investigating other combinatorial therapy strategies with these two cytokine-expressing HSV, which includes sequential administration of the viruses. Consistent with our prior unpublished observations, tumor growth tends to become static or even decrease slightly after each virus dose (see Fig 3) , although the lag period is slightly longer for the day 7 dose than for the day 3 dose. This effect is only observed in the groups treated with cytokine-expressing HSV.
Immunohistochemical analysis of Neuro-2a flank tumors treated with a single dose of M002 in combination with M010 revealed a rapid influx of both CD4 þ and CD8 þ T cells into the tumors by day 3, which was not observed in any of the other treatment groups. Both cell populations remained consistently elevated, with CD8 þ levels higher at the earlier time points (days 3 and 6) and CD4 þ T cell levels higher at the latter time points (days 10 and 13). Of the single HSV treatment groups, only M002 (IL-12-expressing HSV)-treated tumors exhibited similar influx of CD4 þ and CD8 þ T-cell subsets, and HSV-1 expressing CCL2 and IL-12 for antitumor therapy JN Parker et al only at the last time point assessed (day 13). In addition, only M002 in combination with M010 treatment group had significant CD4 þ T-cell responses still detected at day 13 after treatment.
The differences between the effector cell populations elicited over time by the different treatment groups may be explained on the basis of differential activation of effector cells infiltrating experimental tumors as has been observed by us [45] [46] [47] [48] and others. Future studies will isolate potential effector cell populations (CD8 þ T cells, macrophages, NK cells) to determine their relative levels of antitumor activation as well as deletion of individual leukocyte subsets to determine the relative contribution of each to the overall antitumor effect.
In conclusion, combination therapy of murine flank neuroblastoma with an HSV-1 expressing CCL2 and an HSV-1 expressing IL-12 was superior to treatment with either virus alone. Immunohistochemical analysis of immune cell infiltrates demonstrated that this combination did indeed impact on the inflammatory cell milieu elicited, as compared to treatment of tumors with an HSV that expresses only IL-12. These data were both reproducible and statistically significant. While the exact mechanism for this improved antitumor therapy remains to be elucidated, these studies do emphasize the importance of combinatorial therapy approaches for improving tumor regression and long-term outcome. 
